The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $117.75

Today's change+0.95 +0.81%
Updated September 23 4:02 PM EDT. Delayed by at least 15 minutes.
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $117.75

Today's change+0.95 +0.81%
Updated September 23 4:02 PM EDT. Delayed by at least 15 minutes.

Taro Pharmaceutical Industries Ltd up (U.S.)$0.95

Taro Pharmaceutical Industries Ltd closed up Friday by (U.S.)$0.95 or 0.81% to (U.S.)$117.75. Over the last five days, shares have lost 0.14% and sit 3.29% above their 52-week low. This security has underperformed the S&P 500 by 33.81% during the last year.

Key company metrics

  • Open(U.S.) $116.19
  • Previous close(U.S.) $116.80
  • High(U.S.) $118.16
  • Low(U.S.) $115.81
  • Bid / Ask-- / --
  • YTD % change-23.81%
  • Volume107,762
  • Average volume (10-day)242,377
  • Average volume (1-month)238,129
  • Average volume (3-month)273,020
  • 52-week range(U.S.) $114.00 to (U.S.) $157.99
  • Beta0.89
  • Trailing P/E9.32×
  • P/E 1 year forward9.15×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $12.63
Updated September 23 4:02 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+56.96%

Based on its net profit margin of 56.96%, Taro Pharmaceutical Industries Ltd is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.67%Sector:HealthcareIndustry:Pharmaceuticals - Diversified

Latest Company News

View more News

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue265258212215
Total other revenue--------
Total revenue265258212215
Gross profit224214171172
Total cost of revenue41444143
Total operating expense83858781
Selling / general / administrative23232423
Research & development20181915
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0030
Other operating expenses, total--------
Operating income182173125134
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax138201164134
Income after tax115189134104
Income tax, total23123030
Net income115189133104
Total adjustments to net income--------
Net income before extra. items115189133104
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items115189133104
Inc. avail. to common incl. extra. items115189133104
Diluted net income115189133104
Dilution adjustment--------
Diluted weighted average shares43434343
Diluted EPS excluding extraordinary itemsvalue per share2.684.413.112.42
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share2.694.413.172.42